Critical Contrast: MDxHealth (NASDAQ:MDXH) vs. Entrada Therapeutics (NASDAQ:TRDA)

MDxHealth (NASDAQ:MDXH – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Volatility & Risk

MDxHealth has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500.

Institutional & Insider Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares MDxHealth and Entrada Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MDxHealth $114.02 million 0.06 -$33.52 million ($0.75) -0.19
Entrada Therapeutics $3.98 million 50.11 -$143.75 million ($3.84) -1.33

MDxHealth has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for MDxHealth and Entrada Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MDxHealth 1 4 1 0 2.00
Entrada Therapeutics 1 2 4 0 2.43

MDxHealth presently has a consensus price target of $1.33, indicating a potential upside of 825.28%. Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 248.72%. Given MDxHealth’s higher probable upside, equities analysts plainly believe MDxHealth is more favorable than Entrada Therapeutics.

Profitability

This table compares MDxHealth and Entrada Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MDxHealth -40.84% N/A -27.78%
Entrada Therapeutics -4,057.98% -64.00% -50.49%

Summary

MDxHealth beats Entrada Therapeutics on 9 of the 14 factors compared between the two stocks.

About MDxHealth

(Get Free Report)

MDxHealth is a molecular diagnostics company focused on tests that support the detection and management of urologic cancers, particularly prostate cancer. Its services are intended to help clinicians assess cancer risk and make more informed decisions about biopsies and treatment. The company’s products include SelectMDx, a urine-based test that helps assess the risk of clinically significant prostate cancer, and ConfirmMDx, a tissue-based test that can help guide decisions after a negative prostate biopsy.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.